The Salk Institute for Biological Studies

Other

Toudai Tlo, Ltd.

Mitobridge, Inc.

Purdue Research Foundation

The Samuel Roberts Noble Foundation

University of California

Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

University of Kentucky Research Foundation

Beth Israel Deaconess Medical Center, Inc.

The Salk Institute of Biological Studies

Renew Biopharma, Inc.

Joseph Noel

Marianne Bowman

Joseph Chappell

Kathleen R Manna

Courtney M Starks

Ronald Mark Evans

Michael Downes

Thomas J Baiga

Stephane Richard

Mark G Bock

John F W Keana

Tomohisa Kuzuyama

Joseph Jez

Weiwei Fan

Emi Kanakubo Embler

Mike A Patane

Arthur F Kluge

Richard A Dixon

Natalia Doudareva

Lindsey J Bowman

Mark A Verdicia

Chloe Zubieta

Michael B Austin

Mark A Verdecia

Laura Henry

Nikki M Dellas

Suzanne T Thomas

Kun Ping Lu

Michael Mendez

Michael D Burkart

Gunter Fischer

Andrew Dillin

Matthew Saunders

Kyle Botsch

Florence Pojer

Nancy Anderson Da Silva

Elise Larsen

Javier Pascual Cardenas

Jeremy Lanoiselee

Jean-Luc Ferrer

Mike Austin

Authur F Kluge

Justin Ramsey

Kate Woods

Erik Kapernick

Robert K Suto

Gordon Louie

Janusz M Sowadski

Transgenic plants and methods for terpenoid production leveraging such transgenic plants are provided. Such transgenic plants may comprise a first heterologous nucleic acid encoding a polypeptide having 3-hydroxy-3-methylglutarylCoA reductase activity and a second heterologous nucleic acid encoding a polypeptide that introduces de novo formation of isopentenyl phosphate in the plant. Such de novo IP production may be achieved through the overexpression of phosphomevalonate decarboxylase in conjunction with 3-hydroxy-3-methylglutarylCoA reductase, which can result in up to a 130-fold increase of terpenoid production as compared to a wild-type plant.

Methods and platforms for sustainable high yield terpenoid production

Provided herein are compounds and compositions useful in increasing PPAR&#x3b4; activity. The compounds and compositions provided herein are useful for the treatment of PPAR&#x3b4; related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

PPAR agonists

The disclosure relates to the biosynthesis of cannabinoids and related prenylated phenolic compounds using recombinant enzymes. In particular, the disclosure provides recombinant mutant ORF2 enzymes engineered to produce a greater amount of a desired product, or to have a greater ability to catalyze a reaction using a desired substrate, as compared to WT ORF2. The disclosure also provides methods of preparing such ORF2 mutant enzymes; as well as methods of use thereof in improving the biosynthesis of cannabinoids and related prenylated phenolic compounds.

Compositions and methods for using genetically modified enzymes

The present invention relates to methods for producing polyketide synthase variants, and for altering the activity and/or substrate specificity of putative native and variant polyketide synthases. The present invention further relates to compositions comprising said polyketide synthase variants, compounds prepared using said polyketide synthase variants, and uses of said polyketide synthase variants. In one embodiment, said polyketide synthase variant is 2-pyrone synthase.

Polyketide synthase variants and uses thereof

Provided herein are methods and compositions relating to the synthesis of isoprenoid diphosphates using a mutated isopentenyl phosphate kinase.

Methods and isolated protein compositions for isoprenoid diphosphate synthesis

Methods and composition for isoprenoid diphosphate synthesis

Disclosed herein is a method for synthesizing terpenoid compounds, as well as compositions comprising terpenoids and methods for their use. In one aspect the process is represented by the scheme   and

Method for making terpene derivatives

The disclosure provides methods and compositions useful for screening inhibitors of aggregation mediated proteotoxicity. The disclosure provides transgenic animals and cell useful for such screening. Also provided are compounds useful for inhibiting aggregation mediated proteotoxicity in a subject.

Methods for screening and compounds that protect against amyloid diseases

The invention is directed to peptide modulators of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer or neurodegenerative disease.

Pin1-modulating compounds and methods of use thereof

CHI like fatty acid binding proteins and genes, recombinant cells and organisms, methods of metabolic pathway engineering to improve lipid production in cells, Crystal structures of CHI like fatty acid binding proteins, methods of engineering CHI like fatty acid binding proteins and systems thereof are provided.

Metabolic engineering of lipid metabolism by improving fatty acid binding and transport

This disclosure provides crystalline flavonoid or flavanone isomerases, isolated non-native isomerase having the structural coordinates of said crystalline isomerase, and nucleic acids encoding such non-native isomerase. Also disclosed are methods of predicting the activity and/or substrate specificity of a putative isomerase, methods of identifying potential ismerase substrates, and methods of identifying potential isomerase inhibitors.

Chalcone isomerase polypeptides and crystals thereof

The present invention provides compositions comprising the ligand binding domain (LBD) of a farnesoid X receptor (FXR) in crystalline form. In alternative embodiments, the LBD of FXR is complexed with a ligand therefor. There are provided high resolution structures of FXR complexed with a novel high affinity agonist fexaramine. The discovered structure of a FXR LBD provides the first three-dimensional view of the structural basis for FXR ligand binding. The present invention further provides a computer for producing a time-dimensional representation of FXR or a complex thereof, and a computer for determining at least a portion of the structure coordinates of FXR or a complex thereof. The present invention further provides methods of using this structural information to predict molecules capable of binding to FXR; to identify compounds with agonist, antagonist or partial agonist activity for FXR; and to determine whether a test compound is capable of binding to the LBD of FXR. The present invention further provides compositions comprising compounds identified by such invention methods.

Structure of the farnesoid X receptor ligand binding domain and methods of use therefor

Growing community of inventors

San Diego, CA, United States of America

Joseph Noel